Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Johannes Georg Stirnkorb
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Johannes Georg Stirnkorb wrote the following 2 articles about Parkinson Disease.
+ Citations + Abstracts
1 Article SNPs in Aβ clearance proteins: Lower CSF Aβ 2017

Brockmann, Kathrin / Lerche, Stefanie / Dilger, Sarah Selina / Stirnkorb, Johannes Georg / Apel, Anja / Hauser, Ann-Kathrin / Liepelt-Scarfone, Inga / Berg, Daniela / Gasser, Thomas / Schulte, Claudia / Maetzler, Walter. ·From the Center of Neurology, Department of Neurodegenerative Diseases, and Hertie Institute for Clinical Brain Research (K.B., S.L., S.S.D., J.G.S., A.A., A.-K.H., I.L.-S., D.B., T.G., C.S., W.M.), and German Center for Neurodegenerative Diseases (DZNE) (K.B., S.L., A.A., A.-K.H., I.L.-S., T.G., C.S.), University of Tübingen · and Department of Neurology (D.B., W.M.), Christian-Albrechts University, Kiel, Germany. ·Neurology · Pubmed #29117956.

ABSTRACT: OBJECTIVE: To evaluate whether genetic variants in β-amyloid (Aβ) clearance proteins are associated with CSF levels of Aβ METHODS: We analyzed genetic variants known to be involved in Aβ clearance in a PD group comprising 456 patients, 103 of them with dementia. Single nucleotide polymorphisms in the genes RESULTS: Risk variants in the genes CONCLUSIONS: This study suggests that genetic variants associated with Aβ clearance are involved in the pathogenesis of dementia in PD and possibly influence the onset of dementia.

2 Article Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. 2014

Maetzler, Walter / Apel, Anja / Langkamp, Markus / Deuschle, Christian / Dilger, Sarah Selina / Stirnkorb, Johannes Georg / Schulte, Claudia / Schleicher, Erwin / Gasser, Thomas / Berg, Daniela. ·Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany ; DZNE, German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany. · Mediagnost, Reutlingen, Germany. · Department of Internal Medicine IV, University Hospital Tuebingen, Tuebingen, Germany. ·PLoS One · Pubmed #24586351.

ABSTRACT: Naturally occurring autoantibodies (NAbs) against a number of potentially disease-associated cellular proteins, including Amyloid-beta1-42 (Abeta1-42), Alpha-synuclein (Asyn), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and S100 calcium binding protein B (S100B) have been suggested to be associated with neurodegenerative disorders, in particular Alzheimer's (AD) and Parkinson's disease (PD). Whereas the (reduced) occurrence of specific NAbs in AD is widely accepted, previous literature examining the relation of these NAb titres between PD patients and controls, as well as comparing these levels with demographic and clinical parameters in PD patients have produced inconsistent findings. We therefore aimed, in a cross-sectional approach, to determine serum titres of the above NAbs in a cohort of 93 PD patients (31 of them demented) and 194 controls. Levels were correlated with demographic and clinical variables, cerebrospinal fluid Abeta1-42, total tau and phospho-tau levels, as well as with single nucleotide polymorphisms (SNPs) of genes which either have been reported to influence the immune system, the amyloid cascade or the occurrence of PD (ApoE, GSK3B, HLA-DRA, HSPA5, SNCA, and STK39). The investigated NAb titres were neither significantly associated with the occurrence of PD, nor with demographic and clinical parameters, neurodegenerative markers or genetic variables. These results argue against a major potential of blood-borne parameters of the adaptive immune system to serve as trait or state markers in PD.